Alnylam Pharmaceuticals (ALNY) Expected to Announce Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is anticipated to issue its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $1.39 per share and revenue of $943.3730 million for the quarter. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. On average, analysts expect Alnylam Pharmaceuticals to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Down 0.6%

Shares of ALNY opened at $475.91 on Wednesday. The firm has a market cap of $62.38 billion, a P/E ratio of -192.68 and a beta of 0.36. The stock has a 50 day simple moving average of $460.05 and a two-hundred day simple moving average of $365.19. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $495.55.

Analyst Ratings Changes

ALNY has been the subject of several research reports. JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Scotiabank boosted their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research report on Friday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $570.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 10th. Jefferies Financial Group boosted their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a “buy” rating in a research report on Monday, July 7th. Finally, Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a research report on Thursday, July 31st. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $466.92.

Insider Activity

In other news, Director Colleen F. Reitan sold 18,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director directly owned 775 shares of the company’s stock, valued at approximately $362,390. The trade was a 95.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president directly owned 54,052 shares in the company, valued at $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 98,144 shares of company stock valued at $44,160,261. 1.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALNY. Orbis Allan Gray Ltd grew its stake in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the period. Soleus Capital Management L.P. purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth $34,810,000. Hudson Bay Capital Management LP grew its stake in Alnylam Pharmaceuticals by 138.4% in the second quarter. Hudson Bay Capital Management LP now owns 15,348 shares of the biopharmaceutical company’s stock worth $5,005,000 after purchasing an additional 55,348 shares during the period. Alliancebernstein L.P. grew its stake in Alnylam Pharmaceuticals by 49.7% in the second quarter. Alliancebernstein L.P. now owns 67,131 shares of the biopharmaceutical company’s stock worth $21,891,000 after purchasing an additional 22,294 shares during the period. Finally, Boothbay Fund Management LLC grew its stake in Alnylam Pharmaceuticals by 90.4% in the second quarter. Boothbay Fund Management LLC now owns 19,213 shares of the biopharmaceutical company’s stock worth $6,265,000 after purchasing an additional 9,123 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.